VIMIZIM
Biological
BioMarin Pharmaceutical Inc.
Total Payments
$241,345
Transactions
94
Doctors
8
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $241,345 | 94 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $229,422 | 79 | 95.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,775 | 8 | 2.8% |
| Grant | $4,400 | 1 | 1.8% |
| Consulting Fee | $650.00 | 1 | 0.3% |
| Food and Beverage | $97.74 | 5 | 0.0% |
Payments by Type
Research
$229,422
79 transactions
General
$11,923
15 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Morquio A Registry Study (MARS) | BioMarin Pharmaceutical Inc. | $229,422 | 0 |
Top Doctors Receiving Payments for VIMIZIM
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Northbrook, IL | $233,822 | 80 |
| , MD | Clinical Genetics (M.D.) | Chicago, IL | $3,200 | 4 |
| , M.D | Pediatric Orthopaedic Surgery | Uniondale, NY | $2,275 | 2 |
| , MD | Orthopaedic Surgery | Aurora, CO | $1,950 | 3 |
| , DC | Chiropractor | Plainfield, IL | $20.42 | 1 |
| , M.D | Clinical Biochemical Genetics | Chicago, IL | $20.42 | 1 |
| , MD | Clinical Biochemical Genetics | Chicago, IL | $20.41 | 1 |
| , M.D | Neurology | Glenview, IL | $18.25 | 1 |
| Lynda Kolb | Physician Assistant | Glenview, IL | $18.24 | 1 |
Ad
Manufacturing Companies
- BioMarin Pharmaceutical Inc. $241,345
Product Information
- Type Biological
- Total Payments $241,345
- Total Doctors 8
- Transactions 94
About VIMIZIM
VIMIZIM is a biological associated with $241,345 in payments to 8 healthcare providers, recorded across 94 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2024 to 2024. In 2024, $241,345 was paid across 94 transactions to 8 doctors.
The most common payment nature for VIMIZIM is "Unspecified" ($229,422, 95.1% of total).
VIMIZIM is associated with 1 research study, including "Morquio A Registry Study (MARS)" ($229,422).